Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugs

Kanve N. Suvilesh(Harry S. Truman Memorial Veterans' Hospital), Jussuf T. Kaifi(Harry S. Truman Memorial Veterans' Hospital)

bioRxiv (Cold Spring Harbor Laboratory)

October 21, 2023

10.1101/2023.10.18.562944

Cited by 0

Related Papers

RNA cargos in extracellular vesicles derived from blood serum in pancreas associated conditions

|Scientific Reports|2020|88

PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer

|Cancers|2019|77

Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.

|PubMed|2010|27

Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids

|Clinical Cancer Research|2024|22